ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Multiple Myeloma

Multiple Myeloma

Administration of bb2121, a novel anti–B-cell maturation antigen CAR T-cell therapy, produced anti-tumor responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to interim data from a phase I trial.

The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.

Patients with multiple myeloma may have improved tolerance of panobinostat when combined with low-dose thalidomide and subcutaneous bortezomib, according to the results of the phase I/II MUK-six trial.

Treatment at a facility with a higher patient volume was associated with a lower risk of mortality for patients with multiple myeloma, even after adjustment for sociodemographic and geographic factors and comorbidities.

Longer durations of maintenance therapy with lenalidomide were associated with longer survival among patients who underwent autologous hematopoietic stem cell transplant for multiple myeloma.

Adding daratumumab to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma.

Helping patients through toxicities and discomfort from multiple myeloma and its therapies remains a challenge and must be addressed with supportive care practices.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.